Figure 4.

CFTR-Mediated Halide Transport in EYFP

(A) Schematic diagram depicting the halide assay. (B) Human nasal F508del expressing EYFP. Cells were incubated with 0.3 μM of forskolin, 10 μM amiloride, and 100 μM of niflumic acid. Fluorescence measured in response to exchange of 25 mM of sodium iodide. Fluorescence decrease in human nasal cells, WT (C) and F508del (D), treated with electrostatic particle gapmer-Tat (G10-Tat) or scramble (Scr-Tat). Fluorescence change in nasal cells from healthy donor-WT (E) and nasal cells from a CF patient with F508del mutation (F) treated with no exosomes (NE) or with exosomes packed with gapmer (Exo-G10) or scramble (Exo-Scr). Functional halide assay in nasal cells from healthy donor-WT (G) and nasal cells from a CF patient with F508del mutation (H) treated with no lipid nanoparticles (No-LNP) or with LNPs loaded with gapmer (LNP-G10) or scramble (LNP-Scr). Experiments were performed in triplicate in cells shown with the SEMs and p values from a paired two-sided t test, *p = 0.01, **p $\underset{¯}{\le }$0.05.